title: Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality.
abstract: Cancer interventions often disseminate in the population before evidence of their effectiveness is available. Population disease trends provide a natural experiment for assessing the characteristics of the disease and the potential impact of the intervention. We review models for extracting information from population data for use in economic evaluations of cancer screening interventions. We focus particularly on prostate-specific antigen (PSA) screening for prostate cancer and describe approaches that can be used to project the likely costs and benefits of competing screening policies. Results indicate that the lifetime probability of biopsy-detectable prostate cancer is 33%, the chance of clinical diagnosis without screening is 13%, and the average time from onset to clinical diagnosis is 14 years. Less aggressive screening policies that screen less often and use more conservative criteria (e.g., higher PSA thresholds) for biopsy referral may dramatically reduce PSA screening costs with modest impact on benefit.
authors: Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M2-B230, P.O. Box 19024, Seattle, WA 98109-1024, USA. retzioni@fhcrc.org
authors: Ruth
authors: R
authors: Etzioni
authors: Isabelle
authors: I
authors: Durand-Zaleski
authors: Iris
authors: I
authors: Lansdorp-Vogelaar
mesh_terms: D000328:Adult; D000368:Aged; D001706:Biopsy / Q000191:economics; D003362:Cost-Benefit Analysis; D018450:Disease Progression; D055088:Early Detection of Cancer / Q000191:economics*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000191:economics* / Q000453:epidemiology / Q000473:pathology / Q000628:therapy
chemical_list: D017430:Prostate-Specific Antigen
references: Prev Chronic Dis. 2007 Oct;4(4):A100
references: 17875244
references: Biostatistics. 2010 Oct;11(4):707-19
references: 20530126
references: N Engl J Med. 2009 Mar 26;360(13):1310-9
references: 19297565
references: JAMA. 2002 Jul 17;288(3):321-33
references: 12117397
references: J Natl Cancer Inst. 1995 Mar 1;87(5):354-60
references: 7531773
references: Ann Intern Med. 2009 Nov 17;151(10):738-47
references: 19920274
references: N Engl J Med. 2005 May 12;352(19):1977-84
references: 15888698
references: Am J Epidemiol. 1992 Dec 15;136(12):1423-36
references: 1288272
references: N Engl J Med. 1997 Jul 31;337(5):295-300
references: 9233866
references: Cancer Causes Control. 1998 Oct;9(5):519-27
references: 9934717
references: Ann Intern Med. 2012 Jul 17;157(2):120-34
references: 22801674
references: JAMA. 1992 Apr 22-29;267(16):2215-20
references: 1372942
references: Ann Intern Med. 2013 Feb 5;158(3):145-53
references: 23381039
references: J Natl Cancer Inst. 2002 Jul 3;94(13):981-90
references: 12096083
references: Cancer. 2012 Dec 1;118(23):5955-63
references: 22605665
references: Cancer. 2007 May 1;109(9):1877-86
references: 17372918
references: N Engl J Med. 2009 Mar 26;360(13):1320-8
references: 19297566
references: Cancer. 2010 Feb 1;116(3):544-73
references: 19998273
references: J Natl Cancer Inst. 2009 Mar 18;101(6):374-83
references: 19276453
references: Biometrics. 2008 Mar;64(1):10-9
references: 17501937
references: J Natl Cancer Inst. 2003 Jul 2;95(13):981-9
references: 12837834
references: J Urol. 2010 Sep;184(3):907-12
references: 20643434
references: Ann Intern Med. 2008 Nov 4;149(9):659-69
references: 18838717
references: Gastroenterology. 2010 Aug;139(2):698
references: 20600066
references: N Engl J Med. 2003 Jul 17;349(3):215-24
references: 12824459
references: Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):740-50
references: 21546365
references: N Engl J Med. 2005 Oct 27;353(17):1784-92
references: 16251534
references: J Am Stat Assoc. 2008;103(481):259-270
references: 24453387